Literature DB >> 28043148

Analysis of differentially co-expressed genes based on microarray data of hepatocellular carcinoma.

Y Wang, T Jiang, Z Li, L Lu, R Zhang, D Zhang, X Wang, J Tan.   

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide. Although great progress in diagnosis and management of HCC have been made, the exact molecular mechanisms remain poorly understood. The study aims to identify potential biomarkers for HCC progression, mainly at transcription level. In this study, chip data GSE 29721 was utilized, which contains 10 HCC samples and 10 normal adjacent tissue samples. Differentially expressed genes (DEGs) between two sample types were selected by t-test method. Following, the differentially co-expressed genes (DCGs) and differentially co-expressed Links (DCLs) were identified by DCGL package in R with the threshold of q < 0.25. Afterwards, pathway enrichment analysis of the DCGs was carried out by DAVID. Then, DCLs were mapped to TRANSFAC database to reveal associations between relevant transcriptional factors (TFs) and their target genes. Quantitative real-time RT-PCR was performed for TFs or genes of interest. As a result, a total of 388 DCGs and 35,771 DCLs were obtained. The predominant pathways enriched by these genes were Cytokine-cytokine receptor interaction, ECM-receptor interaction and TGF-β signaling pathway. Three TF-target interactions, LEF1-NCAM1, EGR1-FN1 and FOS-MT2A were predicted. Compared with control, expressions of the TF genes EGR1, FOS and ETS2 were all up-regulated in the HCC cell line, HepG2; while LEF1 was down-regulated. Except NCAM1, all the target genes were up-regulated in HepG2. Our findings suggest these TFs and genes might play important roles in the pathogenesis of HCC and may be used as therapeutic targets for HCC management.

Entities:  

Keywords:  EGR1 FOS.; LEF1; differential co-expression; hepatocellular carcinoma; transcription factor

Mesh:

Year:  2017        PMID: 28043148     DOI: 10.4149/neo_2017_207

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  5 in total

1.  Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma.

Authors:  Hui Zhang; Changhua Zhuo; Dong Zhou; Fan Zhang; Minyong Chen; Shaohua Xu; Zhaoshuo Chen
Journal:  Oncol Lett       Date:  2019-04-12       Impact factor: 2.967

2.  Prognostic targets recognition of rectal adenocarcinoma based on transcriptomics.

Authors:  Xingcheng Yi; Yulai Zhou; Hanyu Zheng; Luoying Wang; Tong Xu; Cong Fu; Xiaoyun Su
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

3.  Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.

Authors:  Tong Mou; Di Zhu; Xufu Wei; Tingting Li; Daofeng Zheng; Junliang Pu; Zhen Guo; Zhongjun Wu
Journal:  World J Surg Oncol       Date:  2017-03-16       Impact factor: 2.754

Review 4.  Differential Co-Expression Analyses Allow the Identification of Critical Signalling Pathways Altered during Tumour Transformation and Progression.

Authors:  Aurora Savino; Paolo Provero; Valeria Poli
Journal:  Int J Mol Sci       Date:  2020-12-12       Impact factor: 5.923

5.  Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis.

Authors:  Lei Zhou; Juanni Li; Xing Liu; Yongzhong Tang; Tunliang Li; Huiyin Deng; Jia Chen; Xinlin Yin; Kuan Hu; Wen Ouyang
Journal:  Cell Death Discov       Date:  2022-01-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.